Criteria to qualify for study: Drug used in study:
  • Relapsed of refractory after at least 2 prior lines of therapy including rituximab and alkylating agents. Includes follicular NHL, MZL, WM, SLL

LYM 145

Efficacy and safety stuydy of Tenalisib (RP6530), a novel PI3K dual inhibitor in Patients with relapsed/refractory indolent Non-Hodgkin Lymphoma (iNHL).

Criteria to qualify for study: Drug used in study:
  • Treated with an anthracycline and anti CD20 agent; relapsed or refractory disease after at least 2 lines of therapy or autologous stem cell transplant.

LYM 146

A safety trial of Lisocabtagene Maraleucel (JCAR017) for relapsed and refractory (R/R) B-Cell Non – Hodgkin Lymphoma (NHL) in the outpatient setting.

Criteria to qualify for study: Drug used in study:
  • DLBCL, Relapsed or Refractory

LYM 120 TG Therapeutics UTX-TGR-205

A Phase 2b Randomized Study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma

Refractory/ Aggressive

Criteria to qualify for study: Drug used in study:
  • R/R, AML/MM/DLBCL

HEMREF 51 Medimmune

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients with Selected Relapsed/Refractory Hematological Malignancy "ECOG 0-1, Liver Function Tests: AST and ALT ? 3 × ULN; ? 5 × the ULN for either value if due to leukemia or lymphoma involvement, and serum TBL ? 1.5 × ULN, unless consistent with Gilbert’s syndrome (ratio between total and direct bilirubin > 5), for which TBL ? 2.5 × ULN is allowed. AML - Hydroxyurea, if clinically indicated, is permitted but must be stopped 24 hours prior to the first scheduled dose of MEDI7247 MM-May have received approved agents or radiation within 14 days OR immunotherapy within 28 days of the first scheduled dose of MEDI7247